# Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder

> **NCT05525637** · PHASE3 · UNKNOWN · sponsor: **Shanghai Haiyan Pharmaceutical Technology Co., Ltd.** · enrollment: 1041 (estimated)

## Conditions studied

- Insomnia Disorder

## Interventions

- **DRUG:** YZJ-1139 20mg
- **DRUG:** YZJ-1139 40mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05525637
- **Lead sponsor:** Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-17
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 1041 (ESTIMATED)
- **Last updated:** 2024-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05525637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05525637, "Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05525637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*